Your session is about to expire
← Back to Search
Fadraciclib for Cancer
Study Summary
This trial is studying a new cancer drug to see if it is safe and works well.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have HIV with an uncontrolled viral load and take medication that could affect metabolism.I have active hepatitis B or C.I have an ongoing inflammatory bowel condition or had a GI perforation recently.I had another cancer but it was either in situ, nonmelanoma skin cancer, or I've been cancer-free and without treatment for 2 years.My advanced cancer has worsened despite standard treatments, or I can't tolerate them.I don't have any health or mental conditions that could affect the study.I have not had major surgery in the last 4 weeks.I have stable, treated brain metastases or have been checked and don't have brain metastases.I am currently on IV antibiotics for an infection.I am 18 years old or older.I haven't had cancer treatments or still have side effects within the last 3 weeks.I am fully active or can carry out light work.I do not have diseases that affect my stomach or intestines' ability to absorb medication.I can swallow pills and don't have major stomach or bowel issues affecting medicine absorption.I have heart problems that affect my daily activities.I haven't been vaccinated for COVID-19 in the last 3 months and might have been exposed to it recently.
- Group 1: Phase I Dose escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are in this experiment?
"Yes, the information available on clinicaltrials.gov suggests that this research is actively searching for subjects. The trial was originally posted on July 12th 2021 and updated most recently on April 1st 2022. There are 2 locations involved in the study, and a total of 330 participants are needed between both sites."
Are there other drugs that have been studied in combination with Fadraciclib?
"Fadraciclib was first researched in 2015 by the Dana-Farber Cancer Institute. In subsequent years, 5 further clinical trials have been conducted with many of these taking place in Duarte, California."
Are patients being enrolled in this trial at this time?
"The trial, which can be found on clinicaltrials.gov, is looking for volunteers. The listing was first posted on July 12th 2021 and updated most recently on April 1st 2022."
Is this the first time this experiment has been conducted?
"Fadraciclib clinical trials began in 2015. The first trial, sponsored by Cyclacel Pharmaceuticals, Inc., occurred that same year and involved 70 patients. After the initial study yielded positive results, Fadraciclib received Phase 1 drug approval in 2015. As of now, there are five ongoing trials for this medication taking place across three countries and five cities."
Share this study with friends
Copy Link
Messenger